EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma

Blood

Volumn 111, Issue 7, 2008, Pages 3770-3777

  Moarbess, Georges ^a   El Hajj, Hiba ^b   Kfoury, Youmna ^b   El Sabban, Marwan E ^b   Lepelletier, Yves ^c   Hermine, Olivier ^c   Deleuze Masquéfa, Carine ^a   Bonnet, Pierre Antoine ^a   Bazarbachi, Ali ^b  

^a Laboratoire de Pharmacochimie   (France)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; EAPB 0203; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; N METHYL 1 (2 PHENETHYL)IMIDAZO[1,2 A]QUINOXALIN 4 AMINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; EAPB0203; IMIQUIMOD; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL X;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; CELL DIVISION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; INFLAMMATION; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; METASTASIS; PATHOLOGY; SKIN TUMOR; T CELL LEUKEMIA LYMPHOMA;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CASPASES; CELL DIVISION; CYTOCHROMES C; G2 PHASE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INFLAMMATION; INHIBITOR OF APOPTOSIS PROTEINS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; NF-KAPPA B; QUINOXALINES; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43549098321     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-121913     Document Type: Article

References (30)

1. Rudy SJ. Imiquimod (Aldara): modifying the immune response. Dermatol Nurs. 2002;14:268-270.
2. Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003;149:5-8.
3. Hengge UR, Cusini M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br J Dermatol. 2003;149:15-19.
4. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55:234-240.
5. Steinmann A, Funk JO, Schuler G, Von den Driech P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000;43:555-556.
6. Bong AB, Bonnekoh B, Franke I, Schon M.P, Ulrich J, Gollnick H. Imiquimod, atopical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135-138.
7. Ugurel S, Wagner A, Phohler C, Tilgen W, Reinhold U. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol. 2002;147:621-624.
8. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolamine. Cancer Res. 1992;52:2528-2533.
9. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K. Small anti-viral compounds activate immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205:135-138.
10. Schon M, Bong AB, Drewniok C, et al. Tumor selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-1149.
11. Morjarial S, Deleuze-Masquefa C, Lafont V, et al. Impairment of TNF-alpha production and action by imidazo[1,2-alpha] quinoxalines, a derivative family which displays potential anti-inflammatory properties. Int J Immunopathol Pharmacol. 2006;19:525-538.
12. Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res. 2001;78:79-92.
13. Wattel E, Vartanian JP, Pannetier C, Wain-Hodson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69:2863-2868.
14. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immol. 2001;19:475-496.
15. Kfoury Y, Nasr R, Hermine O, de The H, Bazarbachi A. Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway. Cell Death Differ. 2005;12(suppl 1):871-877.
16. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
17. Shimoyama M. Treatment of patients with adult T-cell leukemia-lymphoma: an overview. In: Takatsuki K, Hinuma Y, Yoshida M, eds. Advances in Adult T-Cell Leukemia and HTLV-I Research. Tokyo, Japan: Japan Scientific Societies Press; 1992:43-56.
18. Bazarbachi A, Ghez YD, Lepelletier D, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664-672.
19. El-Sabban ME, Merhi RA, Haidar HA, et al. Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood. 2002;99:3383-3389.
20. L as an inhibitor for cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci U S A. 1997;94:6939-6942.
21. Alam A, Cohen LY, Aouad S, Sekaly RP. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med. 1999;190:1879-1890.
22. Olson NE, Graves JD, Shu GL, Ryan EG, Clark EA. Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol. 2003;170:6065-6072.
23. Kawakami A, Nakashima T, Sakai H, et al. Inhibition of caspase cascade by HTLV-I tax through induction of NF-kappaB nuclear translocation. Blood. 1999;94:3847-3854.
24. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR 7-MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
25. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135-141.
26. Deleuze-Masquefa C, Gerebtzoff G, Subra G, et al. Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. Bioorg Med Chem. 2004;12:1129-1139.
27. Cereseto A, Diella F, Mulloy JC, et al. p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood. 1996;88:1551-1560.
28. Mahieux R, Pise-Masison CA, Lambert PF, et al. Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function. J Virol. 2000;74: 6866-6874.
29. Nasr R, El-Sabban M, Karam J, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene. 2005;24:419-430.
30. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas: Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82.